# A Study Comparing Abelacimab to Dalteparin in the Treatment of Gastrointestinal/Genitourinary Cancer and Associated VTE

Study · id `cardio:ct-nct05171075` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05171075](<https://clinicaltrials.gov/study/NCT05171075>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT05171075

Browse, organ or system: Heart; Blood vessels  
Browse, condition area: Coronary and vascular disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is terminated. It enrolled 417 participants.

## Technical summary

Registry record NCT05171075. Randomized; single masking; primary purpose treatment. Start 2022-09-27 (actual); primary completion 2026-04-10 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; single masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 417 participants (enrolled count; ClinicalTrials.gov record NCT05171075, source copy `cardio:ctgov-nct05171075-2026-04-17`, retrieved 2026-10-31)
- Started: 2022-09-27 (actual) (ClinicalTrials.gov record NCT05171075, source copy `cardio:ctgov-nct05171075-2026-04-17`, retrieved 2026-10-31)
- Primary completion: 2026-04-10 (actual) (ClinicalTrials.gov record NCT05171075, source copy `cardio:ctgov-nct05171075-2026-04-17`, retrieved 2026-10-31)
- Completion: 2026-04-10 (actual) (ClinicalTrials.gov record NCT05171075, source copy `cardio:ctgov-nct05171075-2026-04-17`, retrieved 2026-10-31)
- Countries: United States; Australia; Austria; Canada; China; Czechia; France; Germany; Hungary; Ireland; Italy; Latvia; Netherlands; Norway; South Korea; Spain; Sweden; Switzerland; Taiwan; United Kingdom (ClinicalTrials.gov record NCT05171075, source copy `cardio:ctgov-nct05171075-2026-04-17`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "TERMINATED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05171075-2026-04-17`, retrieved 2026-10-31)

## The registry's words

- Brief title: A Study Comparing Abelacimab to Dalteparin in the Treatment of Gastrointestinal/Genitourinary Cancer and Associated VTE
- Acronym: MAGNOLIA
- Condition: Venous Thromboembolism
- Condition: Deep Venous Thrombosis
- Condition: Pulmonary Embolism
- Intervention (Biological): Abelacimab
- Intervention (Drug): Dalteparin
- Lead sponsor: Anthos Therapeutics, Inc.
- Lead sponsor class: INDUSTRY
- Collaborator: Novartis Pharmaceuticals
- Collaborator class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Deep vein thrombosis (`cardio:deep-vein-thrombosis`)
- Registry condition terms include this condition: Pulmonary embolism (`cardio:pulmonary-embolism`)
- Registry lists this organization as the lead sponsor: Anthos Therapeutics, Inc. (`cardio:org-anthos-therapeutics-inc`)
- Registry lists this organization as a collaborator: Novartis (`cardio:novartis`)

## Provenance

Content hash: 7e6a81c29b4855434772cf54f08aaba626d040d6d2b7ca481ccd6e5713c35fc8
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
